Clinical trial · Observational
Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma
Health-Related Outcomes For Hodgkin's Disease Survivors
NCT00091091CI-TRIAL-00033772completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Assessing the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care. PURPOSE: This clinical trial is studying the long-term effects of treatment in patients who were previously treated for childhood Hodgkin's lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Long-term Effects Secondary to Cancer Therapy in Children | — | UNRESOLVED | — |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| management of therapy complications | Procedure | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
| questionnaire administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All patients
- description
- Self report/Medical record review/ clinical eval
- interventionNames
- Other: medical chart review
- Other: questionnaire administration
- Procedure: management of therapy complications
Primary outcomes (1)
- measure
- Risk for a specific adverse condition until the earliest of death, development of the adverse condition, loss to follow up, or completion of questionnaire
- timeFrame
- length of study
- description
- The calculation of the incidence rates will be done in two ways: (a) using the self-report incidence of adverse conditions; and (b) using the incidence of adverse conditions validated by clinical evaluation.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Contemporary cohort
* At least 5 years since diagnosis of Hodgkin's lymphoma
* Diagnosed between the years 1987-2001
* 21 and under at diagnosis
* No evidence of disease
* Prior treatment on 1 of the following protocols during the years 1987-2001:
* Children's Cancer Group (CCG) CCG-5942, CCG-59704
* Pediatric Oncology Group (POG) POG-8625, POG-8725, POG-9425, POG-9426
* Pediatric Hodgkin's Consortium: VAMP, VEPA, VAMP/COP
* Institutional protocols COPP/ABV, MOPP/ABVD, ABVD
* Childhood Cancer Survivor Study (CCSS) Hodgkin's lymphoma cohort
* Current enrollment in the CCSS
* Diagnosed between the years 1976-1986
* Completed baseline questionnaire at comparable timepoints (as the contemporary cohort) after diagnosis
PATIENT CHARACTERISTICS:
Age
* Any age
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specifiedReferences
Publications (0)
Data not yet available
No reference posted for this study.